Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective DOI Creative Commons
Xiangchang Zeng, Deliang Huang, Zhibin Zhu

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Май 26, 2025

Liver fibrosis is a common response to chronic liver injury due multiple etiologies and plays crucial in the progression of disease cirrhosis, hepatocellular carcinoma, other liver-related clinical outcomes. Currently, available treatments block are designed eliminate underlying causes disease. The lack truly effective drugs regress or reverse major unmet need. In this context, article briefly describes pathological process hepatic focuses on reviewing progress studies mechanism-based anti-fibrotic drug development therapy, highlighting that positive effect thyroid hormone receptor-β (THR-β) analogs, fibroblast growth factor 21 (FGF21) analogues, Glucagon-like peptide 1 receptor (GLP-1R) agonists, pan-peroxisome proliferator-activated (pan-PPAR) fatty acid synthase (FASN) inhibitors, hydronidone reducing caused by specific etiologies. Moreover, multi-pathway guided combination therapy traditional Chinese medicine demonstrate significant advantages combating fibrosis. Finally, new technologies approaches affecting anti-hepatic were discussed.

Язык: Английский

The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis DOI
Zhongqi Ge, Qingwei Wu,

Chengyu Lv

и другие.

Immunology, Год журнала: 2025, Номер unknown

Опубликована: Май 25, 2025

ABSTRACT Metabolic dysfunction‐associated steatohepatitis (MASH), the progressed period of metabolic steatotic liver disease (MASLD), is a multifaceted characterised by inflammation and fibrosis that develops from simple steatosis, even contributing to hepatocellular carcinoma death. MASH involves several immune cell‐mediated fibrosis, where T cells play crucial role through release pro‐inflammatory cytokines pro‐fibrotic factors. This review discusses complex various cell subsets in pathogenesis highlights progress ongoing clinical trials involving cell‐targeted therapies.

Язык: Английский

Процитировано

0
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective DOI Creative Commons
Xiangchang Zeng, Deliang Huang, Zhibin Zhu

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Май 26, 2025

Liver fibrosis is a common response to chronic liver injury due multiple etiologies and plays crucial in the progression of disease cirrhosis, hepatocellular carcinoma, other liver-related clinical outcomes. Currently, available treatments block are designed eliminate underlying causes disease. The lack truly effective drugs regress or reverse major unmet need. In this context, article briefly describes pathological process hepatic focuses on reviewing progress studies mechanism-based anti-fibrotic drug development therapy, highlighting that positive effect thyroid hormone receptor-β (THR-β) analogs, fibroblast growth factor 21 (FGF21) analogues, Glucagon-like peptide 1 receptor (GLP-1R) agonists, pan-peroxisome proliferator-activated (pan-PPAR) fatty acid synthase (FASN) inhibitors, hydronidone reducing caused by specific etiologies. Moreover, multi-pathway guided combination therapy traditional Chinese medicine demonstrate significant advantages combating fibrosis. Finally, new technologies approaches affecting anti-hepatic were discussed.

Язык: Английский

Процитировано

0